
Clinical Research: Following the Money Phase IV



Ronni Geary, MBA, CPC¹, Philip Eggleton, BBA¹, Matthew Kovak, MS, CCRP¹, Michael Birrer, MD, PhD¹, Nicholas Pruss, BS², Angela Smith, MS, PMP², Zhidan Feng, MS² ¹Cancer Clinical Trials Office, Winthrop P. Rockefeller Cancer Institute ²IT Research Systems, University of Arkansas for Medical Sciences, Little Rock, AR

Background

Prior to the development of the Clinical Research Accounting System (RAS) at UAMS, there was no consistent or efficient method to track incurred clinical trial revenue or expenses. Although in-depth budgets were developed for each clinical trial, there lacked streamlined accounting processes across all clinical research departments for tracking revenue or expenses when they were incurred. We required a system that could efficiently track earned invoiceable, milestone, and start-up revenue while accounting for incurred expenses to allow for appropriate reconciliation of clinical trial accounts. Also needed was an efficient method of comparing earned versus received revenue and incurred versus paid expenses. We needed a system that could help forecast revenue and expenses for a future year for budgeting purposes. Lastly, we had no way to answer campus leadership financial questions without tedious, manual collation of data from multiple systems including the UAMS enterprise finance system (SAP), Clinical Trial Management System (CTMS) and Electronic Medical Record system (EMR).


Home Portfolios	s Studies	Invoices	Payme	nts IDTs	Reports	Administrati	ion Help						
ou are viewing invo		Invoic	e Detai	ls									
XX. The current por CTRA - Industry stu			Invoi	ce Informa	tion		Invoice T	otals	Payme	ent Details		Invoice No	otes
EW study details.		Invoice ID: XXX						ed: \$XXX.XX	Payment ID: X		This invoice has no not		
O BACK to the portfolio.		Invoice Date: XXXX-XX-XX						ed: \$XXX.XX	SAP #: XXXXX				
		SAP In		mber: XXX			e Reinvoice		Date: XXXX-XX				
				Date: XXX			e Adjustme		· · · · ·	/ments: \$XXX.X			
nly Access				Type: Standard Invoice			Write C		Assigned To Items: \$XXX.XX Residual Amount: \$0.00				
have pern his invoice.				Jame: Unti			rrent Balan		Residual A	mount: \$0.0	00		
yourself	fasan				XXX. XXXX		nem Bulun						
ditor if neces	ssary.			(IRB: XX)	· · · · ·								
			-										
			Current S	tatus: Con	npleted								
A t Study Cale	«		e Items		npleted								
This Study Ir A ht Study Cale Tracker	«	Invoic			Activity Type	Activity Name ◆	Contract Term ♥	Charge Type 🔶 Payee		♦ Date Completed ♦	■ Activity Details	To Be Invoiced ♥	This
idy Cale ker	endar	Invoic	e Items Subject	Subject 🛦	Activity		Contract _≜ Term	Charge _♦ Payee		■ Date Completed ♥	Activity Details	To Be Invoiced	This
study Cale acker ks Dashboa	endar «	Invoic	e Items Subject	Subject 🛦	Activity Type		Contract Term ≑	Charge Type Payee	s 🔶 🛛 Segment,	Date Completed	■ Activity Details	To Be Invoiced ♦	Invoid
Study Cale acker ks 3 Dashboa	endar «	Invoice ID \$	e Items Subject	Subject 🛦	Activity Type	Name 🔻	Contract Term	Type	s 🔶 🛛 Segment,	Completed 🔻	Activity Details	Invoiced 🔻	XXX.X
tudy Cale icker (s Dashboa	endar «	Invoice ID ¢ Study XXX (E)	e Items Subject	Subject 🛦	Activity Type 🔶 Submission Submission	Name 🔍	Contract ≜ Term	Type 1 a) so	s 🔶 🛛 Segment,	Completed XXXX-XX-XX	Activity Details	Invoiced T	This Invoic XXX.X XXX.X XXX.X XXX.X
Study Cale acker ks S Dashboa	endar «	Invoic ID ¢ Study XXX (E) XXX (E)	e Items Subject	Subject 🛦	Activity Type Submission Submission Submission	Name 🔻	Contract Term	Type Clyck I 0 I 0	s 🔶 🛛 Segment,	Completed XXXX-XX-XX XXXX-XX-XX	Activity Details	Invoiced XXX.XX XXX.XX	XXX.X XXX.X
Study Cale acker ks S Dashboa	endar «	Invoic ID Study XXX (E) XXX (E) XXX (E)	e Items Subject	Subject 🛦	Activity Type Submission Submission Submission Annual	Name 🔻	Contract Term	Type Clock I 0 I 0 I 0 I 0	s 🔶 🛛 Segment,	Completed XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX	■ Activity Details	Invoiced XXX.XX XXX.XX XXX.XX	XXX.X XXX.X XXX.X XXX.X
A t Study Cale	endar «	Invoice ID Study XXX (E) XXX (E) XXX (E) XXX (E)	e Items Subject	Subject 🛦	Activity Type Submission Submission Submission Annual Annual	Name 🔻	Contract Term	Type Copy of the second s	s 🔶 🛛 Segment,	Completed XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX	Activity Details	Invoiced XXX.XX XXX.XX XXX.XX XXX.XX	XXX.X XXX.X XXX.X XXX.X XXX.X
udy Cale cker s Dashboa	endar «	Invoice ID Study XXX (E) XXX (E) XXX (E) XXX (E) XXX (E) XXX (E)	e Items Subject	Subject Reg ID 🔶	Activity Type Submission Submission Submission Annual Annual Amendment	Name IRB Fee Original/Initial Submission Pharmacy Fee IRB Fee Pharmacy Fee Amendment		Type Clock I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0	s 🔶 🛛 Segment,	Completed XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX	Activity Details	Invoiced XXX.XX XXX.XX XXX.XX XXX.XX XXX.XX XXX.XX	XXX.X XXX.X XXX.X XXX.X XXX.X XXX.X
Study Cale acker ks S Dashboa	endar «	Invoice ID Study XXX (E) XXX (E) XXX (E) XXX (E) XXX (E) XXX (E)	e Items	Subject Reg ID 🔶	Activity Type Submission Submission Submission Annual Annual Amendment	Name IRB Fee Original/Initial Submission Pharmacy Fee IRB Fee Pharmacy Fee Amendment Protocol A7	Term V	Type Clock I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0	s Segment, Cycle	Completed XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX XXXX-XX-XX	Activity Details	Invoiced XXX.XX XXX.XX XXX.XX XXX.XX XXX.XX	XXX.) XXX.) XXX.) XXX.) XXX.) XXX.)

Goals and Metrics

We started with the goal of creating a streamlined system to track clinical trial revenue and manage receipt of payments. Our next goal was tracking expenses related to clinical trials. One of the biggest goals we tackled to date is the creation of an income statement. Our current goals include the creation of a balance sheet and the ability to forecast revenue and expenses for a future year to assist in annual departmental budgeting. We also want the ability to track unfunded procedures.

Outcomes

Since the inception of this software application, we have been able to successfully track, report and post revenue and expenses for our clinical trials. Comprehensive integration with Workday and the CTMS reduced routine and often duplicative manual processes. We are now financially managing 220 Oncology Clinical Trial accounts (Industry, Cooperative, and Investigator Initiated) and have been able to adequately and comprehensively track revenue and report expenses related to clinical trials. We have an income statement that can be executed per study, disease type, study type, or for all studies with activity in the chosen time range. This has allowed for more accurate and timely reporting of financial reports to leadership.



Future Directions

Phase 4 of this project is in discussions. This phase will bring balance sheets as well as forecasting abilities that can be run per study, disease type, study type, or for all studies with activity in the chosen time range which will be integral in our communication with campus financial leadership.

Enhancements are ongoing and additional features will be implemented as we progress forward.

Methods

Our first goal was achieved by linking our custom-developed CTMS with our new accounting system allowing us to track exactly which procedures were completed for which participant. We were also able to link and track study revenue and expenses such as annual continuing reviews. Tracking patient-related expenses was achieved by pulling data from the already-integrated charge master.

Contact

Ronni Geary, MBA, CPC, Clinical Research Finance Manager Philip Eggleton, BBA, Clinical Research Financial Analyst

Cancer Clinical Trials Office Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences 4301 West Markham, Slot 724, Little Rock, AR 72205 (501) 686-8274 – cctrafinance2@uams.edu